Kenvue has been the center of various speculative movements, including a takeover and a class action lawsuit. It has also drawn interesting shifts in investment:
Handelsbanken Fonder AB, Principal Securities Inc., Alberta Investment Management Corp, and Truist Financial Corp all bolstered their stakes in the firm, while some like
Principal Financial, Palouse Capital Management Inc. and Sanctuary Advisors LLC reduced their holdings. Among many expectations, Kenvue's ambitious plans were highlighted, especially with products like
Tylenol and
Neutrogena. At the shareholder level, value has been underlined, but a looming challenge is Kenvue's forecasted profit drop in 2025 due to a stronger dollar. Yet, despite its Q4 earnings matching estimates and Q4 sales missing targets, the financial world is keenly observing Kenvue's potential as a turnaround stock and as an intriguing dividend growth prospect beyond 2025. The company's stock has also attracted both bears and bulls on Wall Street, showing mixed reviews from analysts. However, amidst the aforementioned points, the firm also declares a $0.205 quarterly dividend reflecting a strong consumer health portfolio.
Kenvue KVUE News Analytics from Thu, 17 Oct 2024 07:00:00 GMT to Sat, 22 Feb 2025 10:21:25 GMT -
Rating 2
- Innovation 5
- Information 4
- Rumor 1
